Illumina and Amgen co-developed the test, which will determine whether metastatic colorectal cancer patients will benefit from Vectibix.

At issue is the lack of reference samples for evaluating the performance of LDTs that may determine which patients are appropriate for specific cancer drugs.  

The companies plan to codevelop Adaptive's ClonoSeq assay to measure minimal residual disease in ALL.